Vizsgálati helyszín
Polyclinique Bordeaux Nord Aquitaine
Bordeaux, 33077, FranciaországMég nincs intézményhez kötve
- 21futó vizsgálat
- 6lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 27 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis11 vizsgálat
- 2. fázis8 vizsgálat
- Állapot
- Toboroz9 vizsgálat
- Még nem toboroz7 vizsgálat
- Lezárult6 vizsgálat
- Fut, nem toboroz5 vizsgálat
- Fő szponzor
- UNICANCER4 vizsgálat
- Fondation Franc.Cancerologie Digestive2 vizsgálat
- Hoffmann-La Roche2 vizsgálat
- Institut Curie2 vizsgálat
- Intergroupe Francophone du Myelome2 vizsgálat
- és még 14
Futó vizsgálatok
Még nem toboroz
Multicenter phase III non-Inferiority trial of treatment reduction in patients with advanced hormonesensitive breast cancer in complete response
2026-526319-12-00· 3. fázis· Unicancer· Forrás
Még nem toboroz
Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer
NCT07151586· 2. fázis· UNICANCER· Forrás
Toboroz
Personalizing chemotherapy selection after surgery for patients with stage III colorectal cancer using a blood test
2025-521045-24-00· 3. fázis· Unicancer· Forrás
Toboroz
Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer
NCT07193394· 2. fázis· Institut Curie· Forrás
Toboroz
Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer
NCT06606730· 3. fázis· UNICANCER· Forrás
Toboroz
Corticodependent or Corticoresistant Brain Radionecrosis After Radiotherapy for Brain Metastases
NCT06471465· 3. fázis· Institut Cancerologie de l'Ouest· Forrás
Toboroz
Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
NCT05973864· 2. fázis· UNICANCER· Forrás
Toboroz
PRODIGE 90 - FFCD 22024 - PREDIR-NEOREC - Neoadjuvant dostarlimab with short course radiotherapy in a watch-and-wait strategy for microsatellite unstable or mismatch repair-deficient locally advanced rectal cancer patients: a randomized phase II trial
2024-510772-20-00· 2. fázis· Centre Hospitalier Universitaire De Dijon· Forrás
Toboroz
Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context
NCT06487078· Pfizer· Forrás
Toboroz
Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC
NCT06078384· 2. fázis· UNICANCER· Forrás
Toboroz
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
NCT06382948· 3. fázis· MedSIR· Forrás
Fut, nem toboroz
Treatment of microstellite stable metastatic colorectal cancer presenting high immune infiltrate with chemotherapy (XELOX or FOLFOX Bevacizumab) and
immunotherapy ( Pembrolizumab)
NCT04262687· 2. fázis· Fondation Franc.Cancerologie Digestive· Forrás
Toboroz
ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients
NCT06195709· 3. fázis· Institut Curie· Forrás
Toboroz
Remotely Supervised Computerized Cognitive Stimulation to Reduce Post-chemotherapy Cognitive Difficulties in Patients Treated for Localized Breast Cancer
NCT06027632· Centre Francois Baclesse· Forrás
Contact: Nadine DOHOLLOU, MD
Toboroz
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
NCT06091865· 3. fázis· Regeneron Pharmaceuticals· Forrás
Contact: Clinical Trials Administrator
Fut, nem toboroz
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
NCT05170204· 3. fázis· Hoffmann-La Roche· Forrás
Még nem toboroz
Electronic MonitorIng of Events for dIffuse Large b Cell LYmphoma
NCT05298293· Weprom· Forrás
Contact: Olivier FITOUSSI, MD
Fut, nem toboroz
MInimal Residual Disease Adapted Strategy
NCT04934475· 3. fázis· Intergroupe Francophone du Myelome· Forrás
Fut, nem toboroz
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
NCT04351555· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
NCT04258137· Institut Bergonié· Forrás
Fut, nem toboroz
Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendations.
NCT04144387· Intergroupe Francophone du Myelome· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek